Scott Kopetz, MD, PhD, FACP
The triplet regimen of encorafenib (Bratovi), binimetinib (Mektovi), and cetuximab (Erbitux) led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF
V600E-mutant metastatic colorectal cancer (CRC) who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.1
Results showed that the triplet therapy was associated with a median overall survival (OS) of 9.0 months compared with 5.4 months for those who received cetuximab/irinotecan-containing treatment (HR, 0.52; 95% CI, 0.39-0.70; P
<.0001). The overall response rate (ORR), as assessed by blinded independent central review (BICR), was 26.1% and 1.9%, respectively (P
Array BioPharma, Inc., the manufacturer of encorafenib and binimetinib, stated in a press release that it intends to submit these data for marketing approval in the second half of 2019.
... to read the full story